Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Reversal test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    151 result(s) found for: Reversal test. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2008-008239-27 Sponsor Protocol Number: SUNDRO Start Date*: 2009-02-13
    Sponsor Name:Technische Universität München
    Full Title: Dosisfindungsstudie Sugammadex und Neostigmin bei geringer neuromuskulärer Restblockade (Sugammadex and Neostigmine dose finding study for reversal of residual neuromuscular blockade)
    Medical condition: Dose finding study for sugammadex and/or neostigmine at residual neuromuscular blockade (whereas residual neuromuscular blockade is defined as a TOF of 0.5 in this study).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057286 Neuromuscular blockade reversal LLT
    9.1 10057286 Neuromuscular blockade reversal PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013499-29 Sponsor Protocol Number: SUNDRO20 Start Date*: Information not available in EudraCT
    Sponsor Name:Technische Universität München
    Full Title: Dosisfindungsstudie für Sugammadex und Neostigmin zur Reversierung einer geringen neuromuskulären Restblockade (train of four ratio 0,2) [Sugammadex and Neostigmine dose finding study for reversal ...
    Medical condition: Dose finding study for sugammadex and/or neostigmine at residual neuromuscular blockade (whereas residual neuromuscular blockade is defined as a TOF of 0.2 in this study).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057286 Neuromuscular blockade reversal LLT
    9.1 10057286 Neuromuscular blockade reversal PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001007-18 Sponsor Protocol Number: 2989 Start Date*: 2005-06-03
    Sponsor Name:Royal Victoria Infirmary
    Full Title: Reversal of warfarin anticoagulation with oral vitamin K: towards a better management of over-anticoagulation
    Medical condition: Patients with thromboembolic disorders are anticogulated with warfarin. However excessive over-anticoagulation can increase the patient risk of bleeding. Oral vitamin K is routinely used for revers...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005052-25 Sponsor Protocol Number: AOP00101 Start Date*: 2015-06-29
    Sponsor Name:AZIENDA OSPEDALIERA DI PADOVA
    Full Title: Total versus corrected body weight for dosage of sugammadex in morbidly obese patients.
    Medical condition: Reversal of rocuronium-induced neuromuscular blockade
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10057286 Neuromuscular blockade reversal PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008475-34 Sponsor Protocol Number: Remi-Sunburn-1 Start Date*: 2009-02-25
    Sponsor Name:Abteilung für Anaesthesie und Intensivmedizin, Medizinische Universität Wien
    Full Title: The effect of remifentanil on the reversal of established sunburn-induced hyperalgesia in human volunteers.
    Medical condition: This is a volunteer study in healthy volunteers. Pain research, reversal of hyperalgesia by IMP is studied
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011599-31 Sponsor Protocol Number: RemiAnes1 Start Date*: 2009-06-26
    Sponsor Name:Abteilung für Anaesthesie und Intensivmedizin, Medizinische Universität Wien
    Full Title: The effect of high-dose remifentanil on the reversal of established capsaicin-induced hyperalgesia in human volunteers
    Medical condition: This is a volunteer study in healthy volunteers. Pain research, reversal of hyperalgesia by IMP ist studied
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002021-35 Sponsor Protocol Number: ANR-1/14 Start Date*: 2014-09-23
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori
    Full Title: Decurarization After Thoracic Anesthesia - A prospective multicenter double-blind randomized trial comparing sugammadex vs neostigmine reversal after thoracic anesthesia
    Medical condition: Neuromuscular block is commonly adopted during general anesthesia to facilitate tracheal intubation, mechanical ventilation and surgical manipulation. At the end of anesthesia it very important to ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004813-41 Sponsor Protocol Number: 1321.3 Start Date*: 2014-05-26
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran ...
    Medical condition: Hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10019524 Hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) PT (Completed) SE (Completed) ES (Completed) FI (Completed) EE (Completed) LV (Prematurely Ended) CZ (Completed) IT (Completed) SK (Completed) NL (Completed) BE (Completed) AT (Completed) NO (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-018214-19 Sponsor Protocol Number: 1 Start Date*: 2010-03-01
    Sponsor Name:Centre Hospitalier Universitaire DE NANCY
    Full Title: Étude sur la relation dose-effet de la néostigmine pour l’antagonisation des faibles niveaux de curarisations résiduelles induites par l’atracurium
    Medical condition: -Anesthésie générale; 2-Traitement par blocage neuromusculaire
    Disease: Version SOC Term Classification Code Term Level
    12.1 10002092 Anaesthesia and allied procedures HLT
    12.1 10057291 Reversal of curarization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005410-19 Sponsor Protocol Number: HH-AT-001 Start Date*: 2013-03-11
    Sponsor Name:Jessaziekenhuis Hasselt
    Full Title: Developing a Patient Model of Controlled, Radial Artery Access Site Bleeding for Deciding on Anticoagulation Reversal in Patients Treated by Systemic Anticoagulants.
    Medical condition: With the novel oral anticoagulants, including EDOXABAN-DABIGATRANRIVAROXABAN- APIXABAN, we are entering a new era of anticoagulation for atrial fibrillation (AF) (and deep vein thrombosis). Neve...
    Disease: Version SOC Term Classification Code Term Level
    15.1 10022891 - Investigations 10060319 Anticoagulation drug level therapeutic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004704-34 Sponsor Protocol Number: RECIR Start Date*: 2021-03-16
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Recovery from deep neuromuscular blockade using different sugammadex doses in elderly patients undergoing laparoscopic robot-assisted prostatectomy: a prospective, randomized, double-blind clinical...
    Medical condition: Deep neuromuscular block in patients undergoing RALP under general anaesthesia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10057286 Neuromuscular blockade reversal PT
    Population Age: Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001965-17 Sponsor Protocol Number: AITT2013/5 Start Date*: 2013-09-26
    Sponsor Name:Debreceni Egyetem Orvos- és Egészségtudományi Centrum Aneszteziológiai és Intenzív Terápiás Tanszék
    Full Title: Incidence of postoperative residual neuromuscular blockade following the administration of rocuronium: A randomized placebo controlled study.
    Medical condition: The effect of sugammadex and neostigmin on postoperative residual neuromuscular blockade will be investigated, therefore the patients suffering from various conditions undergoing surgery in general...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10042613 - Surgical and medical procedures 10057286 Neuromuscular blockade reversal PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000379-96 Sponsor Protocol Number: INnaloxonePed-1 Start Date*: 2017-05-05
    Sponsor Name:Karolinska University Hospital
    Full Title: Pharmacokinetic and pharmacodynamic aspects in children after intranasal administration of the opioid antagonist naloxone
    Medical condition: Pharmacokinetic profile after nasal naloxone administration in Children. In second part study reversal of sedation after opioid use
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003605-13 Sponsor Protocol Number: Remi-Capsaicin-2 Start Date*: 2008-12-03
    Sponsor Name:Abteilung für Anaesthesie und Intensivmedizin, Medizinische Universität Wien
    Full Title: The effect of remifentanil on the reversal of established capsaicin-induced hyperalgesia in human volunteers
    Medical condition: This is a volunteer study in healthy volunteers. Pain research, reversal of hyperalgesia by IMP is studied.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004549-14 Sponsor Protocol Number: Remi-Capsaicin-1 Start Date*: 2008-02-15
    Sponsor Name:Department of Anaesthesie, General Intensive Care and Pain Therapy, Medical University of Vienna [...]
    1. Department of Anaesthesie, General Intensive Care and Pain Therapy, Medical University of Vienna
    2.
    Full Title: A novel role for remifentanil: the reversal of established capsaicin-induced hyperalgesia.
    Medical condition: This is a volunteer study in healthy volunteers. Pain research, reversal of hyperalgesia by IMP is studied.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001201-27 Sponsor Protocol Number: P07038 Start Date*: 2011-11-07
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA
    Full Title: A randomized, controlled, parallel-group, double-blind trial of sugammadex or usual care (neostigmine or spontaneous recovery) for reversal of rocuronium- or vecuronium-induced neuromuscular blocka...
    Medical condition: not applicable
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NL (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002204-24 Sponsor Protocol Number: 1160.203 Start Date*: 2014-12-17
    Sponsor Name:University Medical Center Groningen
    Full Title: REVERSAL OF ANTICOAGULANT EFFECT OF DABIGATRAN® BY PROTHROMBIN COMPLEX CONCENTRATE (BERIPLEX®) ASSESSED WITH A NOVEL METHOD OF BLOOD LOSS MEASUREMENT
    Medical condition: Healthy male volunteers. Study assessing the effect of a single 50IU/Kg dose of Beriplex on the anticoagulant effect of Dabigatran. This is of interest when rapid reversal of its effect is mandate...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005116-41 Sponsor Protocol Number: AOP0071 Start Date*: 2015-06-24
    Sponsor Name:University of Padova
    Full Title: Postoperative pulmonary function in patients undergoing laparoscopic sleeve gastrectomy after administration of sugammadex and neostigmine. A double-blind, randomized controlled trial.
    Medical condition: Reversal of rocuronium-induced neuromuscular blockade
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000401-50 Sponsor Protocol Number: CT-PED-2010-01 Start Date*: 2011-08-09
    Sponsor Name:Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
    Full Title: Efficacy and safety of reversal with Sugammadex (BRIDION®) from deep Neuromuscular Blockade induced by rocuronium in children
    Medical condition: Neuromuscular Blockade induced by Rocuronium
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10057286 Neuromuscular blockade reversal PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004457-92 Sponsor Protocol Number: PB2452-PT-CL-0004 Start Date*: 2020-12-02
    Sponsor Name:SFJ Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Open-Label, Single-Arm Study of PB2452 in Ticagrelor-Treated Patients with Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure ...
    Medical condition: Uncontrolled Major or Life Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10053756 Invasive procedure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) AT (Completed) NL (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 16:25:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA